GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 103 filers reported holding GRITSTONE ONCOLOGY INC in Q2 2021. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,169,126 | -14.1% | 1,261,120 | -2.6% | 0.00% | 0.0% |
| Q2 2023 | $2,526,102 | +127674.5% | 1,295,437 | +82.1% | 0.00% | 0.0% |
| Q1 2023 | $1,977 | +651.7% | 711,218 | +831.8% | 0.00% | – |
| Q4 2022 | $263 | -100.0% | 76,331 | -74.0% | 0.00% | – |
| Q3 2022 | $754,000 | -71.5% | 293,459 | -73.1% | 0.00% | -100.0% |
| Q2 2022 | $2,641,000 | +6.4% | 1,091,467 | +81.1% | 0.00% | +100.0% |
| Q1 2022 | $2,482,000 | -1.2% | 602,544 | +119.0% | 0.00% | -50.0% |
| Q2 2021 | $2,512,000 | -59.3% | 275,123 | -57.9% | 0.00% | -50.0% |
| Q1 2021 | $6,166,000 | +1264.2% | 653,920 | +469.7% | 0.00% | – |
| Q4 2020 | $452,000 | +164.3% | 114,792 | +77.9% | 0.00% | – |
| Q3 2020 | $171,000 | -85.9% | 64,529 | -64.6% | 0.00% | -100.0% |
| Q2 2020 | $1,210,000 | +1086.3% | 182,218 | +1439.8% | 0.00% | – |
| Q3 2019 | $102,000 | -91.7% | 11,834 | -86.3% | 0.00% | -100.0% |
| Q3 2018 | $1,232,000 | – | 86,522 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |